Modality Solutions Welcomes Sumika Stansbury to its Growing Cold Chain Engineering™ Team
September 9, 2021: Modality Solutions announced that Sumika Stansbury has joined the company as...
read Details
Modality Solutions new white paper details how simulated transport is a valuable technique for determining the physical stability of drug product protein solutions, including vaccines, monoclonal antibodies, antibody-drug conjugates (ADCs), and gene therapies. Large molecule drug products may be susceptible to degradation when exposed to common transport hazards. Simulation testing exposes the product to the concurrent combination of these hazards at worst-case edges of your operating space in the global supply chain. Unlike ASTM-based testing, the hazards are applied with realistic durations and intensities that reflect the supply chain’s risks.
The white paper explains:
“An understanding of these methodologies is vital to ensure the simulated transport hazards reflect the actual cold chain for each therapy. “If correctly planned and executed to be included in the BLA, analytical results from samples exposed to concurrent transport simulation are considered industry best practice.”
— Modality Solutions President, Gary Hutchinson.
Click here to view the Simulated Transport Methodologies White Paper press release.
September 9, 2021: Modality Solutions announced that Sumika Stansbury has joined the company as...
read DetailsIn 2021, Inc. Magazine has again named Modality Solutions to the publication’s annual Inc....
read DetailsJULY 20, 2021: Modality Solutions is pleased to announce the addition of Matthew Coker...
read Details